Trillium Therapeutics Inc (TRIL)

[pfelgueiras]

BOSTON CD47/SIRPa Summit 18–19 March 2020

March 19, 2020 at 9:10 PRESENTATION:
An Insight into Trillium Therapeutics’ Progress and What’s To Come.
SPEAKER: Yaping Shou
Chief Medical Officer
Trillium Therapeutics

Dr. Yaping Shou is the Chief Medical Officer of Trillium Therapeutics, a clinical-stage immune-oncology company developing innate immune checkpoint inhibitors. She has close to 20 years of industry experience spanning clinical development and translational medicine, with a strong focus in oncology. She most recently served as Executive Medical Director with Takeda Pharmaceuticals, and prior to joining Takeda, she held several clinical development positions with increasing responsibilities at Novartis Pharmaceuticals and GlaxoSmithKline.
She received her MD from Zhejiang University School of Medicine and her PhD in Cellular and Molecular Biology from Drexel University College of Medicine and of University Pennsylvania.
She also conducted postdoctoral studies in the Genetics Genetics Branch at the National Cancer Institutes.